Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 nov 2009 - 07:59
Statutaire naam
Crucell N.V.
Titel
Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
Bericht
Leiden, The Netherlands (November 16, 2009) – Global biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced the launch of the global Crucell brand, a consistent identity for its worldwide activities and products. The rebranding is designed to promote recognition of the Crucell name and what it stands for: bringing meaningful innovation to global health, with a focus on combating infectious diseases. The establishment of a strong global brand will significantly support this mission.
Today’s launch is a major landmark in Crucell’s strategy to build a new global organization out of three companies with a common passion for healthcare innovation. This ambitious development started in 2006, when Crucell—then a Dutch company known for its breakthrough technologies—acquired the vaccine companies Berna Biotech of Switzerland, SBL Vaccines of Sweden and Berna Products Corporation in the US. An intensive period of integration has resulted in a resilient and flexible organization geared for optimal performance and sustainable growth.
Datum laatste update: 02 februari 2026